SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust is trending as President Trump's threats of new tariffs on European nations over Greenland escalate geopolitical tensions, leading to a risk-off market sentiment. The community is divided, with some anticipating a significant market pullback, while others view it as a 'buy the dip' opportunity, also noting a Japan-led bond sell-off as a contributing factor. This environment is fueling discussions about broader market volatility and a flight to safe-haven assets.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following Saudi Arabia's approval of its Anktiva-based Bioshield protocol for non-small cell lung cancer and broader cancer treatment, alongside ongoing discussions with the FDA for papillary bladder cancer. The community is passionately discussing the potential for a significant short squeeze, viewing the company as a disruptive force in oncology while expressing strong frustration with perceived FDA delays.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is actively trending amid escalating US-EU trade tensions driven by President Trump's tariff threats over Greenland, sparking a widespread market sell-off and global risk-off sentiment. The investment community is sharply divided between those anticipating a deeper correction for technology and growth stocks and fervent "buy the dip" proponents. Immediate market focus remains on an upcoming Supreme Court ruling regarding tariff authority and a heavy week of earnings reports, amplifying uncertainty.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. (DJT) is trending amidst intense debate spurred by former President Trump's controversial push for tariffs against European nations, reportedly tied to his interest in Greenland and past grievances. This situation has ignited polarized community discussions concerning potential trade wars and geopolitical repercussions, with many weighing economic stability against his "America First" agenda.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Holdings Inc

Ondas Holdings is generating significant buzz following a substantial upward revision to its future revenue outlook and a surging order backlog, further bolstered by a recent large capital raise. The community is actively discussing its promising potential as a rapidly expanding defense and autonomy platform, especially amidst ongoing negotiations for key acquisitions in the critical drone technology sector.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is a major talking point following its J.P. Morgan conference appearance, where investors are eagerly seeking clarity on its strategy for advancing the Matrix-M adjuvant technology and securing new collaborations. Community sentiment is sharply focused on management's pace in realizing pipeline potential, including a recent Pfizer agreement and ongoing Sanofi ventures, with an activist investor's growing stake and significant short interest adding to the intense market watch.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

ProShares Ultra Bloomberg Natural Gas ($BOIL) is trending due to a significant surge in natural gas futures, driven by widespread forecasts for severe arctic cold fronts across the US, intensifying heating demand expectations. The community is actively debating the potential for a powerful short squeeze amidst historically high short interest, while also acknowledging the inherent volatility and decay of leveraged natural gas ETFs like $BOIL, often referred to as a "widow maker". Discussions highlight the impact of this weather event on depleting storage levels, yet some remain cautious, pointing to broader warm winter trends and structural factors like contango, questioning the rally's sustainability.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin (APP) is trending following an investigative report alleging the company's involvement in money laundering for a Southeast Asian gambling group, which has sparked a sharp market sell-off. While some in the community are expressing serious concerns and anticipating further declines, many long-term investors are dismissing the report as a rehashed short attack and are actively buying the dip, expecting a strong rebound following upcoming earnings and management's anticipated defense of the allegations.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending as investors react to a significant patent extension for its key products until 2041, coupled with a bullish preliminary business update accelerating IBSRELA's path to $1 billion in revenue by 2029 and multiple analyst price target upgrades. The community is buzzing with renewed acquisition speculation and optimism over the company's long-term value, despite ongoing discussions about short-term price fluctuations attributed to market dynamics. This confluence of positive developments has many viewing Ardelyx as a significantly undervalued biotech with strong commercial execution.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending after announcing positive data from its placebo-controlled Phase 1 clinical trial of soquelitinib for atopic dermatitis, showing strong efficacy. The community is actively discussing the oral ITK inhibitor's potential in a large market, with many anticipating significant revaluation and partnership opportunities for its novel mechanism of action.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Brookfield Infrastructure Partners (NYSE:BIP) Share Price Crosses Above Fifty Day Moving Average - Should You Sell?

Brookfield Infrastructure Partners (NYSE:BIP) Shares Pass Above 50-Day Moving Average - Here's Why...

Brookfield Infrastructure Partners (TSE:BIP.UN) Stock Passes Above 50 Day Moving Average - What's Next?

Brookfield Infrastructure Partners (TSE:BIP.UN) Stock Price Passes Above Fifty Day Moving Average - What's Next...

Brookfield Infrastructure (TSE:BIPC) Stock Price Down 1% - Time to Sell?

Brookfield Infrastructure (TSE:BIPC) Shares Down 1% - Time to Sell...

Copeland Capital Management LLC Has $59.50 Million Stock Position in Brookfield Infrastructure Co. $BIPC

Copeland Capital Management LLC cut its holdings in shares of Brookfield Infrastructure Co. (NYSE:BIPC - Free Report) by 22.6% in the 3rd quarter, according to the company in its most recent...

Brookfield Infrastructure Co. $BIPC Shares Sold by Harbor Capital Advisors Inc.

Harbor Capital Advisors Inc. cut its holdings in shares of Brookfield Infrastructure Co. (NYSE:BIPC - Free Report) by 76.3% in the third quarter, according to its most recent disclosure with the...

Brookfield Infrastructure Partners LP (NYSE:BIP) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of Brookfield Infrastructure Partners LP (NYSE:BIP - Get Free Report) (TSE:BIP.UN) have earned an average rating of "Moderate Buy" from the nine ratings firms that are presently covering the...

Brookfield Infrastructure Partners LP $BIP Shares Bought by CCLA Investment Management

CCLA Investment Management lifted its position in shares of Brookfield Infrastructure Partners LP (NYSE:BIP - Free Report) (TSE:BIP.UN) by 14.5% in the 3rd quarter, according to its most recent...

Thrivent Financial for Lutherans Increases Stake in Brookfield Infrastructure Co. $BIPC

Thrivent Financial for Lutherans grew its position in Brookfield Infrastructure Co. (NYSE:BIPC - Free Report) by 220.6% during the 2nd quarter, according to the company in its most recent disclosure...

Brookfield Infrastructure Partners (TSE:BIP.UN) Stock Crosses Below Fifty Day Moving Average - What's Next?

Brookfield Infrastructure Partners (TSE:BIP.UN) Stock Passes Below 50-Day Moving Average - Here's Why...

Addenda Capital Inc. Grows Position in Brookfield Infrastructure Partners LP $BIP

Addenda Capital Inc. raised its position in Brookfield Infrastructure Partners LP (NYSE:BIP - Free Report) (TSE:BIP.UN) by 13.8% in the third quarter, according to its most recent Form 13F filing...

Brookfield Infrastructure Corp. engages in the ownership and operation of infrastructure assets through its subsidiaries. Its businesses include transportation, data infrastructure, and energy. It operates through the Brazil and United Kingdom geographical segments. The company was founded on August 30, 2019 and is headquartered in New York, NY.

Current Price	$45.59
Prev Close	$44.64
Open	$44.62
Dividend Yield	4.16%
50-Day Moving Average	$45.41
Beta	0.99
Avg. Volume	531,011.86
PE Ratio	-38.62

52-Week High	$47.71
52-Week Low	$32.08
Market Capitalization	$6.02B
EPS (Annual)	-$4.60
Price to Book	-5.02
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

BIPC
Brookfield Infrastructure Corp - Ordinary Shares - Class A (Subordinate Share)

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BIPC News

BIPCBrookfield Infrastructure Corp - Ordinary Shares - Class A (Subordinate Share)